ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 ...

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC. Topline data from DENALI Part 2 anticipated by year end 2026 with the potenti ...

India, soon to be the cardiovascular disease capital, faces rising heart attack rates, especially among women who experience ...

Indigenous Nigerian food plants show promise in fighting cancer by targeting cell death and inflammation, offering support ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Blueprint Medicines Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...

Breast cancer is caused by the development of malignant cells in the breast. The malignant cells originate in the lining of the milk glands or ducts of the breast (ductal epithelium). Breast ...

SAN Banco Santander, S.A.

The ancient-Greek commandment Know thyself turns out to be a great modern way to become happier, more empathetic, and more successful.